Twelve partner institutions from the United States and Canada are collaborating to develop novel treatments to improve quality of life and long-term survival for patients fighting malignant brain tumors.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
